Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States

Table 1 Comparison of Regimens for Treatment of HCV genotype 1

Regimen	Duration	Side effects	Contraindications	Characteristics that decrease SVR
Peg-IFN + Ribavirin	48 weeks	Fatigue 65 % Headache 43 % Pyrexia 41 % Myalgia 40 % Anxiety 33 % Alopecia 28 % Neutropenia 27 % Rigors 25 % Depression 20 %	Child-Pugh B or C Autoimmune hepatitis Pregnancy or a pregnant partner Neuropsychiatric illness	HIV co-infection Black IL28B-nonCC Cirrhosis
Peg-IFN + Ribavirin + Telaprevir	24 weeks	As above plus Rash 56 % Pruritis 47 % Nausea 39 % Anemia 36 %	Child-Pugh B or C Autoimmune hepatitis Pregnancy or a pregnant partner Neuropsychiatric illness	HIV co-infection Black IL28B-nonCC Cirrhosis
Ledipasvir/Sofosbuvir (Harvoni)	12 weeks or 24 weeks	Headache 14 % Fatigue 13 % Nausea 7 % Insomnia 5 % Diarrhea 3 %	Severe renal impairment	None
Ombitasvir/Paritaprevir/ritonavir/Dasabuvir (Viekira Pak) Ribavirin	12 weeks	Fatigue 34 % Nausea 22 % Pruritis 18 % Skin reactions 16 % Insomnia 14 % Asthenia 14 %	Severe hepatic impairment Pregnancy or a pregnant partner	None
Grazoprevir/Elbasvir (Zepatier) +/- Ribavirin	12 weeks or 16 weeks	Fatigue 5 % Abdominal pain 2 % Diarrhea 2 % Depression 1 % Irritability 1 %	Child-Pugh B or C In patients on Ribavirin: Pregnancy or a pregnant partner	Baseline NS5A polymorphisms

ISSN: 1750-9378